The role of the *CNTNAP2* gene in the development of autism spectrum disorder

Elena V. Valeeva [a,b], Ilnur S. Sabirov [c], Liliya R. Safiullina [c], Dmitriy O. Nikitin [d], Irina I. Semina [a,d], Tim Rees [e], Denis O. Fesenko [f,g], Ildus I. Ahmetov [b,h,1,*]

[a] *Central Research Laboratory, Kazan State Medical University, Kazan 420012, Russia*
[b] *Laboratory of Genetics of Aging and Longevity, Kazan State Medical University, Kazan 420012, Russia*
[c] *Republican Clinical Psychiatric Hospital named after Academician V.M. Bekhterev, Kazan 420012, Russia*
[d] *Pharmacology Department, Kazan State Medical University, Kazan 420012, Russia*
[e] *Department of Rehabilitation and Sport Science, Faculty of Health and Social Sciences, Bournemouth University, Bournemouth BH12 5BB, United Kingdom*
[f] *Engelhardt Institute of Molecular Biology of Russian Academy of Sciences, Moscow 119991, Russia*
[g] *DNA Research Center, LLC, Khimki 141402, Russia*
[h] *Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool L3 5AF, United Kingdom*

ARTICLE INFO

ABSTRACT

Autism spectrum disorder (ASD) is a neurodevelopmental disorder in which genetic and environmental factors interact in its development. Research suggests that the contactin associated protein 2 (*CNTNAP2*) gene may play a role in ASD pathophysiology, yet more studies involving human participants and animal models of autism are needed. One such model may be the use of prenatal valproic acid (VPA) model to induce autism-like behaviors in offspring rats. The aim of this study was twofold: (1) to examine the association of the *CNTNAP2* gene rs2710102 variant with ASD in children; and (2) to examine the effect of prenatal exposure to VPA on *Cntnap2* gene expression in the rat brain. The study included 167 children of European ancestry—81 diagnosed with ASD (20 girls, 61 boys; age 4.9 ± 1.4 years) and 86 controls (44 girls, 42 boys; 5.1 ± 1.2 years). *In vivo* experiments were conducted in 80 rats (40 with the VPA model of autism), with *Cntnap2* gene expression analysis in the amygdala, hippocampus, prefrontal cortex, and cerebellum. Results demonstrated that the frequency of the *CNTNAP2* gene rs2710102 GG genotype was significantly higher in children with ASD when compared with controls (33.3 vs 19.8%; OR=2.03, 95%CI [1.004, 4.102], $p = 0.035$), although, potentially due to bias in cohort selection, in the ASD children this polymorphism did not meet Hardy-Weinberg expectations ($\chi^2 = 5.40$, $p = 0.02$). In addition, *Cntnap2* gene expression was significantly lower ($p < 0.01$) in the amygdala and hippocampus of VPA rats when compared with controls, regardless of sex. These results support previous research and provide evidence for the *CNTNAP2* gene as a risk factor for ASD.

* Correspondence to: Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.
  E-mail address: i.akhmetov@ljmu.ac.uk (I.I. Ahmetov).
[1] ORCID 0000-0002-6335-4020

1. Introduction

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder, characterized by impaired social, verbal, and nonverbal communication, repetitive behavior, and restricted interests (Semina et al., 2019; Hirota & King, 2023). Currently, 1 in 100 children worldwide are diagnosed with ASD (Zeidan et al., 2022). Childhood autism is the most severe form of ASD, usually diagnosed between the ages of 6 and 10, with a higher prevalence in males (Fombonne, MacFarlane, & Salem, 2021)—the average male to female ratio is 4:1 (Werling et al., 2013).

ASD is genetically heterogeneous. According to the Simons Foundation Autism Research Initiative (The SFARI; https://gene.sfari.org/), most of the genes encoding synaptic cell adhesion molecules cause the development of this pathology (Baig et al., 2017). One strong candidate is the contactin associated protein 2 (*CNTNAP2*) gene, which spans 1.5% of chromosome 7 (7q35-q36.1) and is the largest in the human genome (2.3 Mb, 25 exons) (NCBI Gene; https://www.ncbi.nlm.nih.gov/gene/). The gene is expressed at high levels in the central nervous system (in the cerebral cortex and the basal ganglia). *CNTNAP2* interacts with genes associated with ASD that encode voltage-gated potassium channel type 2 and calcium/calmodulin-dependent serine protein kinase (*KCNA2* and *CASK*). The CNTNAP2 protein is a cell adhesion molecule that mediates the interaction between neurons and glia during nervous system development. It is also involved in the localization of potassium channels in differentiating axons (NCBI Gene; https://www.ncbi.nlm.nih.gov/gene/).

Neurobiological studies using animals, and in vivo experiments, show that Cntnap2 contributes to nervous system abnormalities and diseases, including epilepsy, deficits in social interaction, reduced auditory processing and responsiveness to stimuli, and stereotyped behavior (Scott et al., 2020; Scott et al., 2018; Peñagarikano et al., 2011). Cultured induced pluripotent stem cells from a neurotypical patient with a shortened *CNTNAP2* gene showed reduced neurite branching and simplified complex neuronal networks (St George-Hyslop et al., 2023).

Genetic studies suggest a link between intragenic deletions and copy number variants (CNVs) in *CNTNAP2* and developing ASD (Strauss et al., 2006; Bakkaloglu et al., 2008; Nord et al., 2011; O'Roak et al., 2011; Poot et al., 2010). Gene mutations have led to the development of characteristic ASD endophenotypes and associated disorders, such as delayed language development and language processing disorder, stuttering, hyperactivity, intellectual disability, epilepsy, obsessive-compulsive disorder, schizophrenia, bipolar disorder, and anxiety (Strauss et al., 2006; Sehested et al., 2010; Friedman et al., 2008; Gu et al., 2018; Poot, 2017; Smogavec et al., 2016; Enikeeva et al., 2020). Several studies show phenotypic diversity in gene function, reflecting an association with cognitive processes (rs34438057 variant / polymorphism), development of Alzheimer's disease, and associated biochemical changes: beta-amyloid levels and LDL concentrations (rs9271192, rs12154459, and rs117834366 variants) (Gouveia et al., 2022; Jansen et al., 2019; Lee et al., 2018; Moreno-Grau et al., 2019). *CNTNAP2* rs2710119 and rs144958708 variants have also been associated with altered gut microbiota, while rs11773362, rs6944674, and rs1026412 have been associated with the obesity characteristic of ASD patients (Qin et al., 2022; Scepanovic et al., 2019; Huang et al., 2022; Kichaev et al., 2019; Sakaue et al., 2021).

One of the most intriguing SNPs for investigating its association with ASD is the rs2710102 located in the intron 13 of the *CNTNAP2* gene. Although the *CNTNAP2* rs2710102 variant has not exhibited genome-wide association with ASD, it has consistently demonstrated replication, with evidence across various populations, suggesting that the risk allele (G) of the rs2710102 has functional effects. Numerous studies have linked *CNTNAP2* rs2710102 to language impairments, encompassing language development, specific language impairment, oral and written language delay, dyslexia, and age at first words in both healthy populations and individuals with ASD (Alarcón et al., 2008; Newbury et al., 2011; Peter et al., 2011; Whitehouse et al., 2011; Poot, 2014; Uddin et al., 2021). The G allele of *CNTNAP2* rs2710102 has previously been shown to be a risk factor for developmental delay and language impairment in children with ASD, and also leads to specific functional brain changes in ASD patients (Scott-Van Zeeland et al., 2010; Alarcón et al., 2008; Fang et al., 2021; Uddin et al., 2021). It is important to note, however, that several studies have found no association between *CNTNAP2* gene variants and the development of ASD (Toma et al., 2018; Murdoch et al., 2015; Werling et al., 2016). Therefore, additional replication studies involving different ethnicities are needed.

It is well known that the *CNTNAP2* gene is highly conserved between humans and rodents (Abrahams et al., 2007; Poot, 2017). Previous studies using *Cntnap2* knockout rat and mouse models have shown that loss of *Cntnap2* causes autism-related phenotypes (Peñagarikano et al., 2011; Scott et al., 2020). We therefore hypothesized that rats exposed to valproic acid *in utero* (VPA model of autism: Nicolini & Fahnestock, 2018) would have decreased expression of the *Cntnap2* gene in the brain.

The aim of this study was thus twofold: (1) to examine the association of the *CNTNAP2* gene rs2710102 variant with ASD in children; and (2) to examine the effect of prenatal exposure to valproic acid (VPA model of autism) on *Cntnap2* gene expression in the rat brain.

2. Methods

2.1. Ethics Statement

Both (human and animal) studies in the present research were approved by the Ethics committee of the Kazan State Medical University (protocol number 199, 4 January 2016; and protocol number 3, 29 March 2019). The studies were conducted according to the guidelines of the Declaration of Helsinki, and we adhered to the Strengthening The Reporting of Genetic Association Studies (STREGA) guidelines: An extension of the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement recommendations. Written informed consent was obtained from the parents or legal guardians of the children.

2.2. Study samples

2.2.1. Human study participants

The study involved 167 children of European (Russian) ancestry—81 children with diagnosed ASD (20 girls, 61 boys; age 4.9 ± 1.4 years) and 86 controls (44 girls, 42 boys; 5.1 ± 1.2 years) (see Fig. 1). Children diagnosed with ASD underwent hospital examination in the Republican Clinical Psychiatric Hospital (named after Academician V.M. Bekhterev of the Ministry of Health of the Republic of Tatarstan, Kazan) between March 2019 and December 2021. With the child's parent or guardian in attendance, ASD severity was assessed by two board-certified developmental pediatricians, using the Autism Diagnostic Observation Schedule-Second Edition (ADOS-2: Lord et al., 2012). A total of three modules (1, 2, and 3) of the ADOS-2 were used in this study and the appropriate module was selected according to the age and language level of the individual.

Inclusion criteria for participants were (a) a diagnosis of ASD according to the International Classification of Diseases (ICD-10), and (b) an age between 2 and 7 years. Exclusion criteria were any other comorbid condition.

2.2.2. DNA extraction and genotyping

DNA was extracted from saliva samples using LumiPure (Moscow, Russia). *CNTNAP2* rs2710102 was genotyped by multiplex PCR followed by hybridization on low-density biochips (Biochip-IMB, LLC, Moscow).

PCR was performed in 25 μl of the following composition: PCR buffer with HotTaqMulti polymerase, 4 units (Asfogen, Russia), 5 mM $MgSO_4$, 0.2 mM of each of the dNTPs (Sibenzym, Russia), primer mixture, 200 pmol of Cy5-TCATTGGATCTCATTA universal primer, 1 ul of DNA. Amplification was carried out in 0.2 ml PCR-tubes on a SpeedCycler (AnalytikJena, Germany) with the following conditions: 95 °C for 2 min and 50 cycles in the first stage (95 °C for 20 s, 65 °C for 30 s, 66 °C for 30 s, 69 °C for 40 s), then 40 cycles in the second stage (95 °C - 20 s, 56 °C - 30 s, 72 °C - 30 s).

All allele-specific oligonucleotides were produced by Lumiprobe (Russia). The fabrication of hydrogel biochips was carried out on Qarray2 (Genetix, UK) in dust-free cleanrooms, according to the original technology of the IMB RAS, as previously described (Fesenko et al., 2014).

Hybridization. The 30-μl chamber of the biochip was filled with a mixture of the following composition: 7.5 μl formamide, 7.5 μl 20 ×SSPE, 15 μl PCR product. After incubation (10 h, 37 °C) and washing (10 min in 1x SSPE at room temperature), the biochips were washed with distilled water, dried with compressed air, placed in a portable analyzer "Picodetect" (BIOCHIP-IMB, LLC, Moscow) and fluorescence was registered with an exposure of 0.5–2 s. Image analysis was performed using ImaGelStudio software (IMB RAS).

2.2.3. Animal study

Wistar rats were purchased from the Stolbovaya branch office of the Scientific Center for Biomedical Technologies (Federal Medical and Biological Agency, Russia). The animals were individually-housed and maintained at room temperature, with a 12-hour light/12-hour dark cycle, with a complete balanced diet.

In our previous study, the detailed design of the valproic acid (VPA) rat model was described (Semina et al., 2023). Experiments were performed on 80 rats (age 100 ± 3 days): VPA groups with prenatal administration of 500 mg/kg valproic acid on day 13 of pregnancy of their mothers (n = 20 rats of each sex) and control groups with saline at the same time in the same volume (n = 20 rats of each sex) (Fig. 1). The administration of valproic acid on day 13 of gestation is crucial for embryonic brain development. This is because it coincides with the peak of neurogenesis, gene expression in neurotransmitter systems, and the completion of the formation


Fig. 1. Design for Human and Animal Studies.

of the cytoarchitectonics of the fetal cortex and neural tube (Ingram et al., 2000; Schneider & Przewłocki, 2005; pp. 518, 1300; Markram et al., 2008; pp. 453, 1301; Servadio et al., 2016). The offspring of these rats exhibit symptoms similar to those of humans with ASD, such as increased anxiety, antisocial behaviour, and stereotypy (Schneider & Przewłocki, 2005; pp. 518, 1300; Ingram et al., 2000; Nicolini & Fahnestock, 2018). The model has been verified using the material described in a recent study (Semina et al., 2023).

2.2.4. Total RNA extraction, reverse transcription reaction and quantitative PCR

All rats of VPA groups and control groups were decapitated using a guillotine (NPO Open Science, Russia). The brain was removed for subsequent isolation of the prefrontal cortex (PFC), hippocampus, cerebellum, and amygdala. Brain structures were isolated in the cold with separate brain samples from each rat were placed into chilled tubes and frozen at –80 °C.

Total RNA was isolated from each rat structure using the ExtractRNA (BC032, Evrogen, Russia) according to the manufacturer's instructions. The concentration RNA was assessed using a NanoDrop Lite spectrophotometer (ThermoFisher, USA). The reverse transcription reaction was assessed using the moloney murine leukemia virus (MMLV) reverse transcriptase kit (SK021, Evrogen, Russia) and 500 ng of total RNA. The resulting cDNA samples were then subjected to real-time qPCR on a CFX96 (BioRad, USA) using commercial TaqMan kits for the *Cntnap2* (Cat. 4351372, Applied Biosystems, USA) and the *Gapdh* as reference gene (Cat. 4448490, Applied Biosystems, USA) and with TaqMan Fast Advanced MasterMix (Cat. 4444965, Applied Biosystems, USA). Each analysis was performed in duplicate. Relative levels of *Cntnap2* expression were analyzed using the $2^{-\Delta\Delta Ct}$ method [Livak & Schmittgen (2001)].

2.2.5. Statistical analysis

Statistical analyses were conducted using GraphPad Prism 8.0.1 (GraphPad Software, Inc., San Diego, CA, USA) software. We used chi-squared (χ^2) to test for Hardy-Weinberg equilibrium in the human data, developed by Michael H. Court (2005–2008) http://www.tufts.edu/~mcourt01/Documents/Court%20lab%20%20HW%20calculator.xls. The frequencies of genotypes and alleles were compared between children with autism and controls using Fisher's exact test. The relationship between *CNTNAP2* genotypes and ASD severity was performed using multiple regression analysis (adjusted for age and sex). A nominal association was considered significant at $p < 0.05$. The normality of human data was assessed using the Shapiro–Wilk test. In the rat data, we compared gene expression between VPA rats and controls using Student's t-test, with a Bonferroni correction for multiple tests across the four brain structures of interest, meaning that results were considered statistically significant if their p-values fell below an alpha of 0.00625 (i.e., 0.05/[4 brain structures * 2 sexes]). Data are presented as mean ± SEM.

3. Results

3.1. Human study

The rs2710102 polymorphism of the *CNTNAP2* gene met Hardy-Weinberg expectations in the control group (χ^2 =1.21, p = 0.27), but not in children with ASD (χ^2 =5.40, p = 0.02). The frequency of the *CNTNAP2* gene rs2710102 GG (risk) genotype was significantly higher in the children with ASD when compared with controls (33.3% vs 19.8%; OR=2.03, 95% CI [1.004, 4.102], $p = 0.035$) (see Table 1). There was no association between the *CNTNAP2* gene rs2710102 polymorphism and ASD severity (adjusted for age and sex).

3.2. Animal study

Relative *Cntnap2* mRNA expressions in VPA rats and controls are shown separately in female (Fig. 2a) and male (Fig. 2b) rats. The hippocampal *Cntnap2* gene expression was significantly lower in VPA rats compared to controls in both females (0.14 ± 0.03 vs. 1.00 ± 0.08; $p = 5.1 \times 10^{-5}$) and males (0.34 ± 0.05 vs. 1.00 ± 0.19; $p = 6.0 \times 10^{-4}$). Similar differences in relative *Cntnap2* gene expression were observed in the amygdala in both females (0.26 ± 0.07 vs. 1.00 ± 0.19; $p = 0.0068$) and males (0.14 ± 0.02 vs. 1.00 ± 0.26; $p = 3.0 \times 10^{-4}$). After adjustment for multiple testing, these differences remained significant in male rats only ($p < 0.00625$). In the cerebellum, only male VPA rats had significantly lower *Cntnap2* gene expression compared to controls (0.19 ± 0.05 vs. 1.00 ± 0.17, $p = 0.002$). In female VPA rats, there was a trend towards increased gene expression in the cerebellum (1.37 ± 0.34 vs. 1.00 ± 0.11, $p = 0.0241$). No significant differences were observed in the prefrontal cortex of rats.

Table 1
Genotype Distribution and Allele Frequencies of CNTNAP2 rs2710102 in Children with ASD and Controls.

Groups	Genotypes			G (risk) allele frequency, %
	GG	GA	AA	
ASD children ($n = 81$)	27 (33.3%)*	30 (37.0%)	24 (29.6%)	51.9
Controls ($n = 86$)	17 (19.8%)	48 (55.8%)	21 (24.4%)	47.7

Note. * $p = 0.035$, statistically significant differences between ASD children and controls.

A.

B.

Fig. 2. Change of Relative Cntnap2 mRNA Expression in Different Brain Structures in VPA and Control Female (a) and Male (b) Rats. *Note.* Data are presented as mean $\pm$ SEM. $*$ $p \leq 0.002$, $**$ $p = 5.1 \times 10^{-5}$, $***$ $p = 0.0068$. PFC = prefrontal cortex.

4. Discussion

In line with previous work, in the present study we observed that the *CNTNAP2* rs2710102 G allele is a risk factor for ASD. Additionally, to the best of our knowledge, this is the first study to demonstrate that prenatal exposure to valproic acid may reduce the expression of the *Cntnap2* gene in the amygdala and hippocampus of rats, regardless of sex. These findings, when considered alongside previous *Cntnap2* gene knockout studies in rodents, indicate that the *CNTNAP2* gene may be implicated in ASD pathophysiology.

CNTNAP2 is highly expressed in brain structures and is also involved in neuronal development, synaptogenesis, and neuronal migration (Peñagarikano et al., 2011). During development, the CNTNAP2 protein acts as a neuronal adhesion molecule and receptor (Strauss et al., 2006). Previously, the *CNTNAP2* rs2710102 G allele was reported to be associated with language disorders, dyslexia, and ASD (Alarcón et al., 2008; Newbury et al., 2011; Peter et al., 2011; Whitehouse et al., 2011; Poot, 2014; Uddin et al., 2021). In our sample, we observed the expected association between the *CNTNAP2* rs2710102 GG genotype and ASD. The role of the *CNTNAP2* rs2710102 gene in contributing to the development of language delay in children with ASD has been shown in previous studies (Alarcón et al., 2008; Fang et al., 2021; Uddin et al., 2021). Another independent polymorphism (i.e., rs7794745 in the *CNTNAP2* gene) has also been shown to have an association with ASD and severity of language impairment in other populations (Nascimento et al., 2016; Uddin et al., 2021; Fang et al., 2021). The above said, there is some debate about the role of these two SNPs. In one meta-analysis (Zhang et al., 2019), these two SNPs (rs2710102 and rs7794745) were not shown to be associated with ASD development; in another meta-analysis (Uddin et al., 2021), these same two SNPs were indeed found to be associated with ASD. Using integrative multiomic analysis, Jang and colleagues (Jang et al., 2023) sought to explain that the development of *Cntnap2*-related ASD is largely due to mitochondrial dysfunction, axonal impairment, and synaptic activity. Panyard and colleagues (Panyard et al., 2021) demonstrated that the G allele of the *CNTNAP2* rs2710102 polymorphism was associated with high levels of the metabolite 3-hydroxy-3-methylglutarate, leading to abnormalities in the cholesterol synthesis pathway and the development of inflammation characteristic of children with ASD (Kwon et al., 2022).

Several studies have found an association between the *CNTNAP2* gene and activity in the brain, using functional magnetic resonance imaging (fMRI). One study demonstrated that variants of the *CNTNAP2* rs7794745 gene were associated with changes in activity of certain regions of the brain that are responsible for language function in healthy volunteers (Tan et al., 2010). Another study found an association between the *CNTNAP2* rs2710102 variant and brain activity in areas related to social and communication skills in children with autism (Scott-Van Zeeland et al., 2010). In particular, children carrying the risk allele (rs2710102 G) were found to have decreased long-range functional connections (i.e., fronto-occipital) but increased short-range functional connections (Scott-Van Zeeland et al., 2010). Importantly, in an animal model, homozygous loss of the *Cntnap2*$^{-/-}$ gene resulted in a reduction in local and distant prefrontal functional connectivity. This suggests that neurodevelopmental disorders and autism can be explained by selective

dysregulation of connections in integrative prefrontal areas (Liska et al., 2018).

The role and functions of *Cntnap2* can be studied by knocking out the gene in animals. Knocking out (KO) the *Cntnap2* gene in mice leads to various phenotypic changes, including impaired social behaviour, communication, learning, and memory. A complete KO in mice led to epileptic seizures and a reduction in the number of interneurons. Neuronal migration was impaired, and the activity of the neural network was abnormal (Peñagarikano et al., 2011). In another study, *Cntnap2* KO in rats and mice affected behavior and electroencephalogram scores in the same way, but with differences in phenotypic expression. *Cntnap2* KO rats exhibited severe motor seizures, hyperactivity, and increased consolidation of wakefulness and REM sleep. Although *Cntnap2* KO mice did not show any seizure-like events, they showed hypoactivity and fragmentation of wakefulness (Thomas et al., 2017). In a study by Poulin and Fox (2021), gene knockout rat models showed a deficit in social interaction and increased repetitive and anxious behavior. *Cntnap2* KO mice showed deficiencies in silent gap detection but a surprising superiority in pitch discrimination over control animals. Stereological analysis revealed a reduction in the number and density of neurons. There was also a shift in the size distribution of neurons towards smaller neurons in the medial geniculate nucleus of mutant mice (Truong et al., 2015). Knocking out the *Cntnap2* gene also affects learning and memory. *Cntnap2* KO mice have problems learning new tasks and remembering and recalling information (Rendall et al., 2016). These findings suggest that this gene is important for normal brain development and function, particularly in social behavior and communication. They also highlight the link between changes in the *CNTNAP2* gene and different aspects of ASD.

Our previous work with these rats demonstrated that prenatal administration of valproic acid induced behavioural changes characteristic of autistic patients (Semina et al., 2023). More specifically, VPA rats showed impaired social and anxiety behaviour. Male and female rats prenatally administered valproic acid at a dose of 500 mg/kg showed increased contact with a familiar non-social object in the Three-Chamber Social Test. In addition, the VPA rats showed a preference for closed arms in the Elevated Plus Maze Test. Mitsuhashi et al. (2023) discovered changes in social interaction in mice that received valproic acid at a lower concentration from embryonic day 1 to birth. Male mice showed a preference for a new object (an unfamiliar mouse), and there were no differences in arm preference in the Elevated Plus Maze between control and test mice (Mitsuhashi et al., 2023). The observed differences may be attributed to interspecific convergence and differences between rats and mice (Viggars et al., 2023; Till et al., 2022), as well as variations in the route, duration, and dosage of valproic acid administration.

The present study suggests that the reduction in hippocampal and amygdala *Cntnap2* gene expression in rats in the VPA model of autism could result from several factors. First, the hippocampus and the amygdala are key structures associated with social behavior and emotional responses (Machado et al., 2008; Jonason & Enloe, 1971). The hippocampus plays an important role in memory formation and learning, as well as in the regulation of emotions and stress (Kim & Diamond, 2002). The amygdala is involved in processing emotional signals and forming social bonds (Machado et al., 2008; Jonason & Enloe, 1971). Changes in expression of the *Cntnap2* gene in these structures may therefore disrupt these functions. Second, valproic acid may have a direct effect on expression of the *Cntnap2* gene. Valproic acid affects DNA methylation, which can lead to changes in gene activity, including *Cntnap2* (Wang et al., 2010; Hamza et al., 2017). Valproic acid can directly reduce *Cntnap2* gene expression in the hippocampus and amygdala (Lauber et al., 2016; Zang et al., 2022). Finally, genes associated with ASD often show vulnerability to the environment and stress (Hamza et al., 2017). The VPA rat model of autism can create stressful conditions for brain development, which can lead to altered *Cntnap2* gene expression in the hippocampus and amygdala (Zang et al., 2022). Overall, the reduction in *Cntnap2* gene expression in the rat hippocampus and amygdala in the VPA model of autism may be the result of the interaction of several factors, including the role of these structures in social behavior and emotional responses, the direct effect of valproic acid on *Cntnap2* gene expression, and the effects of stress and the environment on susceptibility.

It was noted a decade ago that the cerebellum plays an important role in cognitive processes and social behaviour (Becker & Stoodley, 2013; Basson & Wingate, 2013). Cerebellum aberrant development has been observed in individuals with ASD (Scott et al., 2009; Sathyanesan et al., 2019). Furthermore, prenatal administration of VPA in mice models has resulted in cerebellar developmental defects and an impaired gene expression profile (Becker & Stoodley, 2013; Basson & Wingate, 2013; Guerra et al., 2023). In particular, Wang and colleagues (2018) observed premature migration of granular cell precursors and a decrease in the number of Purkinje cells (PC) in the cerebellar cortex, which correlates with their impaired synaptic functionality. The *Cntnap2* gene is highly expressed in PC and regulates their morphology (Gogolla et al., 2009; Wang et al., 2018). Other studies have demonstrated that *Cntnap2* KO mice show changes in cerebellar volume and defects in cerebellar sensory learning (Ellegood & Crawley, 2015; Kloth et al., 2015). Further, several studies have noted that *Cntnap2* expression in various brain tissues of the KO model is sex-dependent (Dawson et al., 2023; Schaafsma et al., 2017; Townsend & Smith, 2017). Townsend and Smith (2017) observed that mutations of *Cntnap2* had a stronger effect on the functional responses of cortical circuits and its expression in male mice than in female mice. In contrast to female mice, reduced expression of *Cntnap2* only in KO or heterozygous male mice resulted in reduced visually evoked activity in upper visual areas associated with the dorsal stream. The sex specificity of *Cntnap2* expression was also demonstrated in a mice model by Schaafsma and colleagues (2017). These authors demonstrated that corticotropin receptor 1-releasing hormone (*Crhr1*) expression was increased in males whose mothers experienced early stress-induced maternal immune activation (Schaafsma et al., 2017). A neurobiological study found that male *Cntnap2* KO mice microglia showed increased activated morphology and phagocytosis of synaptic structures compared to wild type (WT) mice, although no differences were observed in female KO and WT mice (Dawson et al., 2023). The above examples notwithstanding, there is a lack of data on sex-dependent changes in *Cntnap2* expression in the cerebellum. In the present study, we used rats that were exposed prenatally to valproic acid to complement previous findings. In a study by Ojiro and colleagues (2022) the cerebral cortex of male rats showed a significant 0.65-fold downregulation in *Cntnap2* expression when offspring of post-pubertal male rats were orally administered a high dose (900 mg/kg) of valproic acid for 28 days (Ojiro et al., 2022). Our results indicate that only males showed a significant decrease in *Cntnap2* expression in the cerebellum, while females tended to show an increase. This observation may be related to the influence of sex hormones. Hoffman et al. (2016) demonstrated the effect of 17β-estradiol on

experiments with danio-mutant *cntnap2* fish. The mutants had a deficit of inhibitory neurons and impaired regulation of signal transduction in excitatory and inhibitory neurons, leading to the nocturnal hyperactivity observed in individuals with ASD. Estrogen receptor agonists suppressed this phenotype (Hoffman et al., 2016). Furthermore, it is possible that sex hormones may influence *Cntnap2* gene expression in cerebellar tissue through perinatal effects of testosterone in males, which contribute to the development of differences in male and female microglia throughout the cerebellum (McCarthy et al., 2017). According to Donna M. Werling's hypothesis, however, such an observed difference may be modulated by natural sexually dimorphic processes in sexually dimorphic microglia, specifically the prenatal effects of VPA on *Cntnap2* expression (A.M. Werling et al., 2016; D.M. Werling et al., 2016). Taken together, these findings emphasize the significance of gender as a factor when evaluating the functional activity of a gene in animal models. Further neurobiological studies are required to observe individual brain tissue cell types and explore molecular pathways.

A key strength of the present research is the combined study of the *CNTNAP2* gene in humans and animals. The findings from our human study support previous research and provide evidence for the *CNTNAP2* gene rs2710102 polymorphism as a risk factor for ASD. We also found, in the first study of its kind, that *Cntnap2* gene expression was significantly lower in the amygdala and hippocampus of VPA rats compared to controls, regardless of sex. Against the backdrop of this study's strengths, we should note some potential limitations—the relatively limited sample size of ASD children and controls, and the lack expression in rats at the protein level. Regardless, however, our findings further highlight the importance of the *CNTNAP2* gene in ASD and its potential link to the changes in brain activity seen with this disorder.

CRediT authorship contribution statement

Liliya R. Safiullina: Data curation. **Ilnur S. Sabirov:** Data curation. **Elena V. Valeeva:** Writing – original draft, Visualization, Investigation, Formal analysis. **Ildus I. Ahmetov:** Writing – review & editing, Supervision, Project administration, Conceptualization. **Denis O. Fesenko:** Investigation. **Tim Rees:** Writing – review & editing. **Irina I. Semina:** Writing – review & editing, Supervision, Project administration, Conceptualization. **Dmitriy O. Nikitin:** Investigation, Data curation.

Declaration of Competing Interest

The authors declare that they have no competing interests.

Data Availability

Data will be made available on request.

Acknowledgements

References

Abrahams, B. S., Tentler, D., Perederiy, J. V., Oldham, M. C., Coppola, G., & Geschwind, D. H. (2007). Genome-wide analyses of human perisylvian cerebral cortical patterning. *Proceedings of the National Academy of Sciences of the United States of America, 104*(45), 17849–17854. https://doi.org/10.1073/pnas.0706128104

Alarcón, M., Abrahams, B. S., Stone, J. L., Duvall, J. A., Perederiy, J. V., Bomar, J. M., Sebat, J., Wigler, M., Martin, C. L., Ledbetter, D. H., Nelson, S. F., Cantor, R. M., & Geschwind, D. H. (2008). Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. *American Journal of Human Genetics, 82*(1), 150–159.

Baig, D. N., Yanagawa, T., & Tabuchi, K. (2017). Distortion of the normal function of synaptic cell adhesion molecules by genetic variants as a risk for autism spectrum disorders. *Brain Research Bulletin, 129*, 82–90. https://doi.org/10.1016/j.brainresbull.2016.10.006

Bakkaloglu, B., O'Roak, B. J., Louvi, A., Gupta, A. R., Abelson, J. F., Morgan, T. M., & Lifton, R. P. (2008). Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. *The American Journal of Human Genetics, 82*(1), 165–173. https://doi.org/10.1016/j.ajhg.2007.09.017

Basson, M. A., & Wingate, R. J. (2013). Congenital hypoplasia of the cerebellum: Developmental causes and behavioral consequences. *Frontiers in Neuroanatomy, 7*, 29. https://doi.org/10.3389/fnana.2013.00029

Becker, E., & Stoodley, C. J. (2013). Autism spectrum disorder and the cerebellum. *International Review of Neurobiology, 113*, 1–34. https://doi.org/10.1016/B978-0-12-418700-9.00001-0

Dawson, M. S., Gordon-Fleet, K., Yan, L., Tardos, V., He, H., Mui, K., Nawani, S., Asgarian, Z., Catani, M., Fernandes, C., & Drescher, U. (2023). Sexual dimorphism in the social behaviour of Cntnap2-null mice correlates with disrupted synaptic connectivity and increased microglial activity in the anterior cingulate cortex. *Communications Biology, 6*(1), 846. https://doi.org/10.1038/s42003-023-05215-0

Ellegood, J., & Crawley, J. N. (2015). Behavioral and neuroanatomical phenotypes in mouse models of autism. *NeuroTherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 12*(3), 521–533. https://doi.org/10.1007/s13311-015-0360-z

Enikeeva, R. F., Kazantseva, A. V., Davydova, J. D., & Khusnutdinova, E. K. (2020). The role of polymorphic variants of the contactin-associated-like protein-2 (CNTNAP2) gene in the formation of differences in anxiety levels. *Research Results in Biomedicine, 6*(1), 20–36. https://doi.org/10.18413/2658-6533-2020-6-1-0-3

Fang, F., Ge, M., Liu, J., Zhang, Z., Yu, H., Zhu, S., Xu, L., & Shao, L. (2021). Association between genetic variants in *DUSP15*, *CNTNAP2*, and *PCDHA* genes and risk of childhood autism spectrum disorder. *Behavioural Neurology, 2021*, Article 4150926. https://doi.org/10.1155/2021/4150926

Fesenko, D., Chudinov, A., Surzhikov, S., Nasedkina, T., & Zasedatelev, A. (2014). Biochip for genotyping SNPs defining core Y-chromosome haplogroups in Russian population groups. BioChip. *Journal, 8*, 171–178. ⟨https://doi.org/10.1007/s13206-014-8303-z⟩.

Fombonne, E., MacFarlane, H., & Salem, A. C. (2021). Epidemiological surveys of ASD: advances and remaining challenges. *Journal of Autism and Developmental Disorders, 51*, 4271–4290. https://doi.org/10.1007/s10803-021-05005-9

Friedman, J. I., Vrijenhoek, T., Markx, S., Janssen, I. M., Van Der Vliet, W. A., Faas, B. H. W., … Veltman, J. A. (2008). CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. *Molecular Psychiatry, 13*(3), 261–266. https://doi.org/10.1038/sj.mp.4002049

Gogolla, N., Leblanc, J., Quast, K. B., Südhof, T. C., & Hensch, T. K. (2009). Common circuit defect of excitatory-inhibitory balance in mouse models of autism. *Journal of Neurodevelopmental Disorders, 1*(2), 172–181. https://doi.org/10.1007/s11689-009-9023-x

Gouveia, C., Gibbons, E., Dehghani, N., Eapen, J., Guerreiro, R., & Bras, J. (2022). Genome-wide association of polygenic risk extremes for Alzheimer's disease in the UK Biobank. *Scientific Reports, 12*(1), 8404. https://doi.org/10.1038/s41598-022-12391-2

Gu, H., Hou, F., Liu, L., Luo, X., Nkomola, P. D., Xie, X., & Song, R. (2018). Genetic variants in the CNTNAP2 gene are associated with gender differences among dyslexic children in China. *EBioMedicine, 34*, 165–170. https://doi.org/10.1016/j.ebiom.2018.07.007

Guerra, M., Medici, V., Weatheritt, R., Corvino, V., Palacios, D., Geloso, M. C., Farini, D., & Sette, C. (2023). Fetal exposure to valproic acid dysregulates the expression of autism-linked genes in the developing cerebellum. *Translational Psychiatry, 13*(1), 114. https://doi.org/10.1038/s41398-023-02391-9

Hamza, M., Halayem, S., Mrad, R., Bourgou, S., Charfi, F., & Belhadj, A. (2017). Implication de l'épigénétique dans les troubles du spectre autistique: revue de la littérature [Epigenetics' implication in autism spectrum disorders: A review]. *L'Encephale, 43*(4), 374–381. https://doi.org/10.1016/j.encep.2016.07.007

Hirota, T., & King, B. H. (2023). Autism spectrum disorder: A review. *JAMA, 329*(2), 157–168. https://doi.org/10.1001/jama.2022.23661

Hoffman, E. J., Turner, K. J., Fernandez, J. M., Cifuentes, D., Ghosh, M., Ijaz, S., Jain, R. A., Kubo, F., Bill, B. R., Baier, H., Granato, M., Barresi, M. J., Wilson, S. W., Rihel, J., State, M. W., & Giraldez, A. J. (2016). Estrogens suppress a behavioral phenotype in zebrafish mutants of the autism risk gene CNTNAP2. *Neuron, 89*(4), 725–733. https://doi.org/10.1016/j.neuron.2015.12.039

Huang, J., Huffman, J. E., Huang, Y., Do Valle, Í., Assimes, T. L., Raghavan, S., Voight, B. F., Liu, C., Barabási, A. L., Huang, R. D. L., Hui, Q., Nguyen, X. T., Ho, Y. L., Djousse, L., Lynch, J. A., Vujkovic, M., Tcheandjieu, C., Tang, H., Damrauer, S. M., Reaven, P. D., … O'Donnell, C. J. (2022). Genomics and phenomics of body mass index reveals a complex disease network. *Nature Communications, 13*(1), 7973. https://doi.org/10.1038/s41467-022-35553-2

Ingram, J. L., Peckham, S. M., Tisdale, B., & Rodier, P. M. (2000). Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. *Neurotoxicology and Teratology, 22*(3), 319–324. https://doi.org/10.1016/s0892-0362(99)00083-5

Jang, W. E., Park, J. H., Park, G., Bang, G., Na, C. H., Kim, J. Y., Kim, K. Y., Kim, K. P., Shin, C. Y., An, J. Y., Lee, Y. S., & Kim, M. S. (2023). Cntnap2-dependent molecular networks in autism spectrum disorder revealed through an integrative multi-omics analysis. *Molecular Psychiatry, 28*(2), 810–821. https://doi.org/10.1038/s41380-022-01822-1

Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., & Posthuma, D. (2019). Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nature Genetics, 51*(3), 404–413. https://doi.org/10.1038/s41588-018-0311-9

Jonason, K. R., & Enloe, L. J. (1971). Alterations in social behavior following septal and amygdaloid lesions in the rat. *Journal of Comparative and Physiological Psychology, 75*(2), 286–301. https://doi.org/10.1037/h0030808

Kichaev, G., Bhatia, G., Loh, P. R., Gazal, S., Burch, K., Freund, M. K., Schoech, A., Pasaniuc, B., & Price, A. L. (2019). Leveraging polygenic functional enrichment to improve GWAS power. *American Journal of Human Genetics, 104*(1), 65–75. https://doi.org/10.1016/j.ajhg.2018.11.008

Kim, J. J., & Diamond, D. M. (2002). The stressed hippocampus, synaptic plasticity and lost memories. *Nature Reviews Neuroscience, 3*(6), 453–462. https://doi.org/10.1038/nrn849

Kloth, A. D., Badura, A., Li, A., Cherskov, A., Connolly, S. G., Giovannucci, A., Bangash, M. A., Grasselli, G., Peñagarikano, O., Piochon, C., Tsai, P. T., Geschwind, D. H., Hansel, C., Sahin, M., Takumi, T., Worley, P. F., & Wang, S. S. (2015). Cerebellar associative sensory learning defects in five mouse autism models. *eLife, 4*, Article e06085. https://doi.org/10.7554/eLife.06085

Kwon, S. J., Hong, K. W., Choi, S., Hong, J. S., Kim, J. W., Kim, J. W., Lee, H. J., Jang, H. B., & Yum, K. S. (2022). Association of 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene polymorphism with obesity and lipid metabolism in children and adolescents with autism spectrum disorder. *Metabolic Brain Disease, 37*(2), 319–328. https://doi.org/10.1007/s11011-021-00877-3

Lauber, E., Filice, F., & Schwaller, B. (2016). Prenatal valproate exposure differentially affects parvalbumin-expressing neurons and related circuits in the cortex and striatum of mice. *Frontiers in Molecular Neuroscience, 9*, 150. https://doi.org/10.3389/fnmol.2016.00150

Lee, J. J., Wedow, R., Okbay, A., Kong, E., Maghzian, O., Zacher, M., … Cesarini, D. (2018). Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nature Genetics, 50*(8), 1112–1121. https://doi.org/10.1038/s41588-018-0147-3

Liska, A., Bertero, A., Gomolka, R., Sabbioni, M., Galbusera, A., Barsotti, N., Panzeri, S., Scattoni, M. L., Pasqualetti, M., & Gozzi, A. (2018). Homozygous loss of autism-risk gene CNTNAP2 results in reduced local and long-range prefrontal functional connectivity. *Cerebral Cortex, 28*(4), 1141–1153. https://doi.org/10.1093/cercor/bhx022

Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods, 25*(4), 402–408. https://doi.org/10.1006/meth.2001.1262

Lord, C., Rutter, M., DiLavore, P.C., Risi, S., Gotham, K., & Bishop, S.L. (2012). Autism Diagnostic Observation Schedule. (2nd ed.). Torrance, CA: Western Psychological Services.

Machado, C. J., Emery, N. J., Capitanio, J. P., Mason, W. A., Mendoza, S. P., & Amaral, D. G. (2008). Bilateral neurotoxic amygdala lesions in rhesus monkeys (Macaca mulatta): consistent pattern of behavior across different social contexts. *Behavioral Neuroscience, 122*(2), 251–266. https://doi.org/10.1037/0735-7044.122.2.251

Markram, K., Rinaldi, T., La Mendola, D., Sandi, C., & Markram, H. (2008). Abnormal fear conditioning and amygdala processing in an animal model of autism. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 33*(4), 901–912. https://doi.org/10.1038/sj.n

McCarthy, M. M., Nugent, B. M., & Lenz, K. M. (2017). Neuroimmunology and neuroepigenetics in the establishment of sex differences in the brain. *Nature Reviews Neuroscience, 18*(8), 471–484. https://doi.org/10.1038/nrn.2017.61

Mitsuhashi, T., Hattori, S., Fujimura, K., Shibata, S., Miyakawa, T., & Takahashi, T. (2023). In utero exposure to valproic acid throughout pregnancy causes phenotypes of autism in offspring mice. *Developmental Neuroscience, 45*(5), 223–233. https://doi.org/10.1159/000530452

Moreno-Grau, S., de Rojas, I., Hernández, I., Quintela, I., Montreal, L., Alegret, M., Hernández-Olasagarre, B., Madrid, L., González-Perez, A., Maroñas, O., Rosende-Roca, M., Mauleón, A., Vargas, L., Lafuente, A., Abdelnour, C., Rodríguez-Gómez, O., Gil, S., Santos-Santos, M.Á., Espinosa, A., Ortega, G., & Ruiz, A. (2019). Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 15*(10), 1333–1347. https://doi.org/10.1016/j.jalz.2019.06.4950

Murdoch, J. D., Gupta, A. R., Sanders, S. J., Walker, M. F., Keaney, J., Fernandez, T. V., Murtha, M. T., Anyanwu, S., Ober, G. T., Raubeson, M. J., DiLullo, N. M., Villa, N., Waqar, Z., Sullivan, C., Gonzalez, L., Willsey, A. J., Choe, S. Y., Neale, B. M., Daly, M. J., & State, M. W. (2015). No evidence for association of autism with rare heterozygous point mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in other contactin-associated proteins or contactins. *PLoS Genetics, 11*(1), Article e1004852. https://doi.org/10.1371/journal.pgen.1004852

Nascimento, P. P., Bossolani-Martins, A. L., Rosan, D. B., Mattos, L. C., Brandão-Mattos, C., & Fett-Conte, A. C. (2016). Single nucleotide polymorphisms in the CNTNAP2 gene in Brazilian patients with autistic spectrum disorder, 10.4238/gmr.15017422 *Genetics and Molecular Research: GMR, 15*(1). https://doi.org/10.4238/gmr.15017422.

NCBI Gene, ⟨https://www.ncbi.nlm.nih.gov/gene/⟩.

Newbury, D. F., Paracchini, S., Scerri, T. S., Winchester, L., Addis, L., Richardson, A. J., Walter, J., Stein, J. F., Talcott, J. B., & Monaco, A. P. (2011). Investigation of dyslexia and SLI risk variants in reading- and language-impaired subjects. *Behavior Genetics, 41*(1), 90–104. https://doi.org/10.1007/s10519-010-9424-3

Nicolini, C., & Fahnestock, M. (2018). The valproic acid-induced rodent model of autism. *Experimental Neurology, 299*(Pt A), 217–227. https://doi.org/10.1016/j.expneurol.2017.04.017

Nord, A. S., Roeb, W., Dickel, D. E., Walsh, T., Kusenda, M., O'connor, K. L., & McClellan, J. M. (2011). Reduced transcript expression of genes affected by inherited and de novo CNVs in autism. *European Journal of Human Genetics, 19*(6), 727–731. https://doi.org/10.1038/ejhg.2011.24

Ojiro, R., Watanabe, Y., Okano, H., Takahashi, Y., Takashima, K., Tang, Q., Ozawa, S., Saito, F., Akahori, Y., Jin, M., Yoshida, T., & Shibutani, M. (2022). Gene expression profiles of multiple brain regions in rats differ between developmental and postpubertal exposure to valproic acid. *Journal of Applied Toxicology: Jatek,, 42*(5), 864–882. https://doi.org/10.1002/jat.4263

O'Roak, B. J., Deriziotis, P., Lee, C., Vives, L., Schwartz, J. J., Girirajan, S., & Eichler, E. E. (2011). Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. *Nature Genetics, 43*(6), 585–589. https://doi.org/10.1038/ng.835

Panyard, D. J., Kim, K. M., Darst, B. F., Deming, Y. K., Zhong, X., Wu, Y., Kang, H., Carlsson, C. M., Johnson, S. C., Asthana, S., Engelman, C. D., & Lu, Q. (2021). Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. *Communications Biology, 4*(1), 63. https://doi.org/10.1038/s42003-020-01583-z

Peñagarikano, O., Abrahams, B. S., Herman, E. I., Winden, K. D., Gdalyahu, A., Dong, H., … Geschwind, D. H. (2011). Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. *Cell, 147*(1), 235–246. https://doi.org/10.1016/j.cell.2011.08.040

Peter, B., Raskind, W. H., Matsushita, M., Lisowski, M., Vu, T., Berninger, V. W., Wijsman, E. M., & Brkanac, Z. (2011). Replication of CNTNAP2 association with nonword repetition and support for FOXP2 association with timed reading and motor activities in a dyslexia family sample. *Journal of Neurodevelopmental Disorders, 3*(1), 39–49. https://doi.org/10.1007/s11689-010-9065-0

Poot, M. (2014). A candidate gene association study further corroborates involvement of contactin genes in autism. *Molecular Syndromology, 5*(5), 229–235. https://doi.org/10.1159/000362891

Poot, M. (2017). Intragenic CNTNAP2 deletions: A bridge too far. *Molecular Syndromology, 8*(3), 118–130. https://doi.org/10.1159/000456021

Poot, M., Beyer, V., Schwaab, I., Damatova, N., van't Slot, R., Prothero, J., & Haaf, T. (2010). Disruption of CNTNAP2 and additional structural genome changes in a boy with speech delay and autism spectrum disorder. *Neurogenetics, 11*, 81–89. https://doi.org/10.1007/s10048-009-0205-1

Poulin, C. J., & Fox, A. E. (2021). Preliminary evidence for timing abnormalities in the CNTNAP2 knockout rat. *Behavioural Processes, 190*, Article 104449. https://doi.org/10.1016/j.beproc.2021.104449

Qin, Y., Havulinna, A. S., Liu, Y., Jousilahti, P., Ritchie, S. C., Tokolyi, A., Sanders, J. G., Valsta, L., Brożyńska, M., Zhu, Q., Tripathi, A., Vázquez-Baeza, Y., Loomba, R., Cheng, S., Jain, M., Niiranen, T., Lahti, L., Knight, R., Salomaa, V., Inouye, M., … Méric, G. (2022). Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. *Nature Genetics, 54*(2), 134–142. https://doi.org/10.1038/s41588-021-00991-z

Rendall, A. R., Truong, D. T., & Fitch, R. H. (2016). Learning delays in a mouse model of Autism Spectrum Disorder. *Behavioural Brain Research, 303*, 201–207. https://doi.org/10.1016/j.bbr.2016.02.006

Sakaue, S., Kanai, M., Tanigawa, Y., Karjalainen, J., Kurki, M., Koshiba, S., Narita, A., Konuma, T., Yamamoto, K., Akiyama, M., Ishigaki, K., Suzuki, A., Suzuki, K., Obara, W., Yamaji, K., Takahashi, K., Asai, S., Takahashi, Y., Suzuki, T., Shinozaki, N., … Okada, Y. (2021). A cross-population atlas of genetic associations for 220 human phenotypes. *Nature Genetics, 53*(10), 1415–1424. https://doi.org/10.1038/s41588-021-00931-x

Sathyanesan, A., Zhou, J., Scafidi, J., Heck, D. H., Sillitoe, R. V., & Gallo, V. (2019). Emerging connections between cerebellar development, behaviour and complex brain disorders. *Nature Reviews Neuroscience, 20*(5), 298–313. https://doi.org/10.1038/s41583-019-0152-2

Scepanovic, P., Hodel, F., Mondot, S., Partula, V., Byrd, A., Hammer, C., Alanio, C., Bergstedt, J., Patin, E., Touvier, M., Lantz, O., Albert, M. L., Duffy, D., Quintana-Murci, L., Fellay, J., & Milieu Intérieur Consortium. (2019). A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals. *Microbiome, 7*(1), 130. https://doi.org/10.1186/s40168-019-0747-x

Schaafsma, S. M., Gagnidze, K., Reyes, A., Norstedt, N., Månsson, K., Francis, K., & Pfaff, D. W. (2017). Sex-specific gene-environment interactions underlying ASD-like behaviors. *Proceedings of the National Academy of Sciences of the United States of America, 114*(6), 1383–1388. https://doi.org/10.1073/pnas.1619312114

Schneider, T., & Przewłocki, R. (2005). Behavioral alterations in rats prenatally exposed to valproic acid: Animal model of autism. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 30*(1), 80–89. https://doi.org/10.1038/sj.n

Scott, J. A., Schumann, C. M., Goodlin-Jones, B. L., & Amaral, D. G. (2009). A comprehensive volumetric analysis of the cerebellum in children and adolescents with autism spectrum disorder. *Autism Research: Official Journal of the International Society for Autism Research, 2*(5), 246–257. https://doi.org/10.1002/aur.97

Scott, K. E., Kazazian, K., Mann, R. S., Möhrle, D., Schormans, A. L., Schmid, S., & Allman, B. L. (2020). Loss of Cntnap2 in the rat causes autism-related alterations in social interactions, stereotypic behavior, and sensory processing. *Autism Research, 13*(10), 1698–1717. https://doi.org/10.1002/aur.2364

Scott, K. E., Schormans, A. L., Pacoli, K. Y., De Oliveira, C., Allman, B. L., & Schmid, S. (2018). Altered auditory processing, filtering, and reactivity in the Cntnap2 knock-out rat model for neurodevelopmental disorders. *Journal of Neuroscience, 38*(40), 8588–8604. https://doi.org/10.1523/JNEUROSCI.0759-18.2018

Scott-Van Zeeland, A. A., Abrahams, B. S., Alvarez-Retuerto, A. I., Sonnenblick, L. I., Rudie, J. D., Ghahremani, D., Mumford, J. A., Poldrack, R. A., Dapretto, M., Geschwind, D. H., & Bookheimer, S. Y. (2010). Altered functional connectivity in frontal lobe circuits is associated with variation in the autism risk gene CNTNAP2. *Science Translational Medicine, 2*(56), 56–80. https://doi.org/10.1126/scitranslmed.3001344

Sehested, L. T., Møller, R. S., Bache, I., Andersen, N. B., Ullmann, R., Tommerup, N., & Tümer, Z. (2010). Deletion of 7q34–q36. 2 in two siblings with mental retardation, language delay, primary amenorrhea, and dysmorphic features. *American Journal of Medical Genetics Part A, 152*(12), 3115–3119. https://doi.org/10.1002/ajmg.a.33476

Semina, I. I., Mukharyamova, L. M., Sabirov, I. S., Valeeva, E. V., Safiullina, L. R., & Nikitin, D. O. (2019). The current state of the problem of autism spectrum disorders—some biomedical and socio-humanitarian aspects. *Kazan Medical Journal, 100*(6), 918–929. https://doi.org/10.17816/KMJ2019-918

Semina, I. I., Valeeva, E. V., Nikitin, D. O., Baichurina, A. Z., Nikitina, A. V., Shilovskaya, E. V., & Kravtsova, O. A. (2023). Sex differences in rats with the valproate model of autism: Disturbances in social behavior and changes in Drd1 gene expression in various brain structures. *Neuroscience and Behavioral Physiology*, 1–12. https://doi.org/10.1007/s11055-023-01458-w

Servadio, M., Melancia, F., Manduca, A., di Masi, A., Schiavi, S., Cartocci, V., Pallottini, V., Campolongo, P., Ascenzi, P., & Trezza, V. (2016). Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. *Translational Psychiatry, 6*(9), Article e902. https://doi.org/10.1038/tp.2016.182

Smogavec, M., Cleall, A., Hoyer, J., Lederer, D., Nassogne, M. C., Palmer, E. E., & Zweier, C. (2016). Eight further individuals with intellectual disability and epilepsy carrying bi-allelic CNTNAP2 aberrations allow delineation of the mutational and phenotypic spectrum. *Journal of Medical Genetics, 53*(12), 820–827. https://doi.org/10.1136/jmedgenet-2016-103880

St George-Hyslop, F., Haneklaus, M., Kivisild, T., & Livesey, F. J. (2023). Loss of CNTNAP2 alters human cortical excitatory neuron differentiation and neural network Development. *Biological Psychiatry*. https://doi.org/10.1016/j.biopsych.2023.03.014

Strauss, K. A., Puffenberger, E. G., Huentelman, M. J., Gottlieb, S., Dobrin, S. E., Parod, J. M., … Morton, D. H. (2006). Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. *New England Journal of Medicine, 354*(13), 1370–1377. https://doi.org/10.1056/NEJMoa052773

Tan, G. C., Doke, T. F., Ashburner, J., Wood, N. W., & Frackowiak, R. S. (2010). Normal variation in fronto-occipital circuitry and cerebellar structure with an autism-associated polymorphism of CNTNAP2. *NeuroImage, 53*(3), 1030–1042. https://doi.org/10.1016/j.neuroimage.2010.02.018

The Simons Foundation Autism Research Initiative, ⟨https://gene.sfari.org/⟩.

Thomas, A. M., Schwartz, M. D., Saxe, M. D., & Kilduff, T. S. (2017). Cntnap2 knockout rats and mice exhibit epileptiform activity and abnormal sleep-wake physiology, 10.1093/sleep/zsw026 *Sleep, 40*(1). https://doi.org/10.1093/sleep/zsw026.

Till, S. M., Hickson, R. D. L., & Kind, P. C. (2022). Cross-species considerations in models of neurodevelopmental disorders. *Trends in Neurosciences, 45*(3), 171–172. https://doi.org/10.1016/j.tins.2021.12.005

Toma, C., Pierce, K. D., Shaw, A. D., Heath, A., Mitchell, P. B., Schofield, P. R., & Fullerton, J. M. (2018). Comprehensive cross-disorder analyses of CNTNAP2 suggest it is unlikely to be a primary risk gene for psychiatric disorders. *PLoS Genetics, 14*(12), Article e1007535. https://doi.org/10.1371/journal.pgen.1007535

Townsend, L. B., & Smith, S. L. (2017). Genotype- and sex-dependent effects of altered Cntnap2 expression on the function of visual cortical areas. *Journal of Neurodevelopmental Disorders, 9*, 2. https://doi.org/10.1186/s11689-016-9182-5

Truong, D. T., Rendall, A. R., Castelluccio, B. C., Eigsti, I. M., & Fitch, R. H. (2015). Auditory processing and morphological anomalies in medial geniculate nucleus of Cntnap2 mutant mice. *Behavioral Neuroscience, 129*(6), 731–743. https://doi.org/10.1037/bne0000096

Uddin, M. S., Azima, A., Aziz, M. A., Aka, T. D., Jafrin, S., Millat, M. S., Siddiqui, S. A., Uddin, M. G., Hussain, M. S., & Islam, M. S. (2021). CNTNAP2 gene polymorphisms in autism spectrum disorder and language impairment among Bangladeshi children: A case-control study combined with a meta-analysis. *Human Cell, 34*(5), 1410–1423. https://doi.org/10.1007/s13577-021-00546-8

Viggars, M. R., Sutherland, H., Cardozo, C. P., & Jarvis, J. C. (2023). Conserved and species-specific transcriptional responses to daily programmed resistance exercise in rat and mouse. *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 37*(12), Article e23299. https://doi.org/10.1096/fj.202301611R

Wang, R., Tan, J., Guo, J., Zheng, Y., Han, Q., So, K. F., Yu, J., & Zhang, L. (2018). Aberrant development and synaptic transmission of cerebellar cortex in a VPA induced mouse autism model. *Frontiers in Cellular Neuroscience, 12*, 500. https://doi.org/10.3389/fncel.2018.00500

Wang, Z., Xu, L., Zhu, X., Cui, W., Sun, Y., Nishijo, H., Peng, Y., & Li, R. (2010). Demethylation of specific Wnt/β-catenin pathway genes and its upregulation in rat brain induced by prenatal valproate exposure. *Anatomical Record, 293*(11), 1947–1953. https://doi.org/10.1002/ar.21232

Werling, A. M., Bobrowski, E., Taurines, R., Gundelfinger, R., Romanos, M., Grünblatt, E., & Walitza, S. (2016). CNTNAP2 gene in high functioning autism: No association according to family and meta-analysis approaches. *Journal of Neural Transmission, 123*, 353–363. https://doi.org/10.1007/s00702-015-1458-5

Werling, D. M., Parikshak, N. N., & Geschwind, D. H. (2016). Gene expression in human brain implicates sexually dimorphic pathways in autism spectrum disorders. *Nature Communications, 7*, Article 10717. https://doi.org/10.1038/ncomms10717

Whitehouse, A. J., Bishop, D. V., Ang, Q. W., Pennell, C. E., & Fisher, S. E. (2011). CNTNAP2 variants affect early language development in the general population. *Genes, Brain, and Behavior, 10*(4), 451–456. https://doi.org/10.1111/j.1601-183X.2011.00684.x

Zang, Z., Yin, H., Du, Z., Xie, R., Yang, L., Cai, Y., Wang, L., Zhang, D., Li, X., Liu, T., Gong, H., Gao, J., Yang, H., Warner, M., Gustafsson, J. A., Xu, H., & Fan, X. (2022). Valproic acid exposure decreases neurogenic potential of outer radial glia in human brain organoids. *Frontiers in Molecular Neuroscience, 15*, Article 1023765. https://doi.org/10.3389/fnmol.2022.1023765

Zeidan, J., Fombonne, E., Scorah, J., Ibrahim, A., Durkin, M. S., Saxena, S., & Elsabbagh, M. (2022). Global prevalence of autism: A systematic review update. *Autism Research, 15*(5), 778–790. https://doi.org/10.1002/aur.2696

Zhang, T., Zhang, J., Wang, Z., Jia, M., Lu, T., Wang, H., Yue, W., Zhang, D., Li, J., & Wang, L. (2019). Association between CNTNAP2 polymorphisms and autism: A family-based study in the Chinese Han population and a meta-analysis combined with GWAS data of psychiatric genomics consortium. *Autism Research: Official Journal of the International Society for Autism Research, 12*(4), 553–561. https://doi.org/10.1002/aur.2078